QHHP Ameliorates MASH Through Modulation of a Cyp4a32-PPARγ-CD36-Associated Lipotoxic Axis.

Authors

Feixiang Xiong, Fengna Yan, Yuyong Jiang, Xiaomin Ji, Tong Wu, Yang Zhou, Xuejie Zhang, Dandan Chen, Juqiang Han, Yixin Hou

Published in

FASEB journal : official publication of the Federation of American Societies for Experimental Biology. Volume 40. Issue 20. Pages e72362. Oct 31, 2026.

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive stage of metabolic dysfunction-associated fatty liver disease, for which effective pharmacological therapies remain limited. Qinggan Huatan Huoxue Prescription (QHHP) has been used clinically in the management of fatty liver disease and related metabolic disorders, but its overall efficacy and underlying mechanisms remain unclear. In this study, the therapeutic effects of QHHP on MASH were evaluated through clinical observation, animal experiments, cellular studies, multi-omics analysis, and computational simulation. QHHP treatment was associated with improved liver function and selected lipid parameters in patients with MASH, attenuated steatosis, inflammation, and fibrosis in HFHC- and MCD-induced mouse models, and reduced PA/OA-induced lipid droplet accumulation in AML12 cells and PMHs. Transcriptomic and pathway analyses indicated the involvement of PPAR signaling and fatty acid metabolism-related pathways. In vivo and in vitro findings showed that QHHP intervention was accompanied by downregulation of Cyp4a32, PPARγ, and CD36. Pathway-intervention experiments further showed that siPPARγ enhanced, whereas Rosiglitazone partially reversed the inhibitory effects of QHHP on lipid droplet accumulation and related molecular expression, suggesting that PPARγ-related lipid uptake signaling participates in its anti-lipotoxic mechanism. QHHP may alleviate hepatic lipotoxic injury through multi-component regulation of a lipid metabolism-related network involving Cyp4a32, PPARγ, and CD36.

PMID:
42876247
Bibliographic data and abstract were imported from PubMed on 15 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.